Ritholtz Wealth Management Invests $488,000 in Electromed, Inc. (NYSE:ELMD)

Ritholtz Wealth Management purchased a new stake in Electromed, Inc. (NYSE:ELMD) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 16,504 shares of the company’s stock, valued at approximately $488,000. Ritholtz Wealth Management owned 0.20% of Electromed as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ELMD. Navellier & Associates Inc. acquired a new stake in Electromed in the third quarter valued at approximately $368,000. State Street Corp grew its holdings in Electromed by 14.5% during the 3rd quarter. State Street Corp now owns 22,066 shares of the company’s stock valued at $474,000 after purchasing an additional 2,800 shares in the last quarter. Barclays PLC purchased a new stake in Electromed during the 3rd quarter worth $215,000. Walleye Capital LLC purchased a new stake in Electromed during the 3rd quarter worth $274,000. Finally, Legacy Wealth Asset Management LLC acquired a new position in Electromed in the 4th quarter worth $253,000. 40.82% of the stock is owned by institutional investors and hedge funds.

Electromed Stock Up 0.4 %

Shares of ELMD opened at $34.00 on Tuesday. The firm has a market cap of $287.64 million, a price-to-earnings ratio of 47.22 and a beta of 0.31. The business’s 50 day moving average is $29.72 and its two-hundred day moving average is $22.46. Electromed, Inc. has a 52-week low of $9.90 and a 52-week high of $34.25.

Electromed (NYSE:ELMD) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.13. The firm had revenue of $14.67 million for the quarter. Electromed had a net margin of 11.34% and a return on equity of 15.32%.

Insider Activity

In related news, Director Andrew Summers sold 17,463 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $30.09, for a total transaction of $525,461.67. Following the sale, the director now directly owns 189,838 shares of the company’s stock, valued at approximately $5,712,225.42. This represents a 8.42 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 14.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded Electromed from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 9th.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.